Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of AUROLENA 5 vs TRAJENTA (linagliptin 5 mg) in healthy Thai adults under fasting conditions
TCTR20241208004Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20241208004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20241208004.